TRV-045 is a small molecule commercialized by Trevena, with a leading Phase I program in Epilepsy. According to Globaldata, it is involved in 3 clinical trials, of which 1 was completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of TRV-045’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for TRV-045 is expected to reach an annual total of $16 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
TRV-045 is under development for the treatment of chemotherapy-induced peripheral neuropathy, diabetic neuropathic pain, chronic pain, inflammatory pain and epilepsy. The drug candidate is a new chemical entity. It acts by targeting S1P receptor. It is administered through oral route. The drug candidate is developed based on ABLE (advanced biased ligand explorer) technology platform.
Trevena is a biotechnology company. It discovers and develops G-protein coupled receptor targeted medicines. The company provides products such as RV045, TRV734 and TRV250. Its TRV045 is an oral drug used for the treatment of acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. Trevena’s TRV734 is also an oral drug which is used in medication- assisted therapy for the treatment of opioid use disorder. The company’s GPCR is associated with beneficial versus adverse biological effects. Its TRV250 is an oral delta opioid biased ligand for treatment of refactory migraine. Trevena is headquartered in Chesterbrook, Pennsylvania, the US.
The company reported revenues of (US Dollars) US$0.4 million for the fiscal year ended December 2022 (FY2022), compared to a revenue of US$0.6 million in FY2021. The operating loss of the company was US$56.4 million in FY2022, compared to an operating loss of US$51.9 million in FY2021. The net loss of the company was US$53.7 million in FY2022, compared to a net loss of US$51.6 million in FY2021.
For a complete picture of TRV-045’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.